EXHIBIT 6

Case 1:01-cv-12257-PBS Document 3725-7 Filed 02/08/07 Page 2 of 6 1/11/2005 Morgan, Patricia Kay - FIRST DATA BANK

00001 1 HIGHLY CONFIDENTIAL - ATTORNEYS' EYES ONLY IN THE UNITED STATES DISTRICT COURT 2 3 FOR THE DISTRICT OF MASSACHUSETTS ----x 4 5 In Re: PHARMACEUTICAL) INDUSTRY AVERAGE WHOLESALE) MDL No. 1456 6 7 PRICE LITIGATION) CIVIL ACTION NO.) 01-CV-12257-PBS 8) 9 THIS DOCUMENT RELATES TO ALL ACTIONS 10 -----x 11 IN THE SUPERIOR COURT FOR THE STATE OF ARIZONA 12 IN AND FOR THE COUNTY OF MARICOPA _____ 13 ROBERT J. SWANSTON, Individually and) on behalf of himself and all others) 14 Similarly situated, 15 Plaintiff,) Case No.) CV2002-004988 16 v. 17) Vol. 1 TAP PHARMACEUTICAL PRODUCTS, INC., et al., 18 Defendants. 19 20 VIDEOTAPED DEPOSITION OF PATRICIA KAY MORGAN New York, New York 21 Tuesday, January 11, 2005 22

C/4599 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:991 1:99

1	Q. When you say populate the database,	1	foundation. If you know.
2	what database are you referring to?	2	A. We request the published price from
3	A. Our national drug data file as the	3 th	ne manufacturer to the wholesaler.
4	master.	4	Q. Great. You said there's a direct
5	Q. What goes into the national drug data	5 pr	rice field?
6	file? What information?	6	A. Correct.
7	A. The NDC number, the product name, the	7	Q. What does that correspond to?
8	Rx, the OTC status, the DEA status, the pricing	8	A. Direct price is for those companies
9	information, the label warnings, the allergy	9 th	nat sell direct. In addition to selling through
10	alerts, the indications, contraindications.	10 wh	nolesalers, or for those that only sell direct
11	There's over 200 data elements per NDC, so	11 ar	nd do not sell through wholesalers.
12	Q. Okay. So it's a database that would	12	Q. And where does the information for
13	be used by a variety of people for a variety of	13 th	hat field come from?
14	different purposes; is that correct?	14	A. It again is defined as the published
15	A. That's correct.	15 di	irect price from the manufacturer to
16	Q. Like a doctor could use it to check	16 no	on-wholesale customers.
17	for contraindications?	17	Q. So you get it from manufacturer price
18	A. Correct.	18 1i	ists?
19	Q. Does it also include pricing	19	A. Correct.
20	information?	20	Q. Calculated WP, what does that refer
21	A. Yes, sir, it does.	21 to	5?
22	Q. What pricing information does it	22	A. It was a field that was in existence

22

1/11/2005 Morgan, Patricia Kay

We have several pricing fields. We

include?

1

19

20

21

22

price, to your knowledge?

have what's known as WHN, which is frequently referred to as WAC or wholesale acquisition cost. We have a direct price field. We have a calculated WP field. We have a Blue Book field. We have a suggested wholesale price field. We have the federal upper limit. 10 And we have the Medicaid AWP field. 11 12 And we have it for both unit and package. 13 WHN, which you said is commonly referred to as WAC, where does the information for that field come from? For the policy it's the published 16 price from the manufacturer to the wholesaler, so 17 it comes from the manufacturer. 18

And that's an undiscounted published

MR. SOBOL: Objection to form.

MR. KERN: Objection, lacks

1/11/2005 Morgan, Patricia Kay

before I arrived. For all purposes now it 1 2 matches our Blue Book field. Okay. SWP, what does that refer to? It's the suggested wholesale price, and it's populated if the manufacturer suggests Q. Some manufacturers include an AWP on their price lists; is that correct? 8 9 Α. A suggested AWP, yes. And that's where you put that into 10 ο. what you call the SWP field? 11 12 A. That's correct. 13 What is Blue Book price? Blue Book is what's become synonymous with AWP to many of our customers, so it is the average wholesale price, so it's the price that 16 includes the markup after our wholesaler survey, 17 18 if the product's available through the wholesaler. 19 20 Q. And what's the federal upper limit 21 price? 22 A. That is a number we populate that's

C প্রপ্ত 1:191 শুড়া 12257-PBS Document 3725-7 Filed 02/08/07005 শুঞ্জু শুড়া ডে পি

1 supplied by CMS for multisource products. 1 Q. So what do you do with it? 2 Q. You get that directly from the 2 Α. The data is entered into the database government? using editor cards, and it populates the fields 3 A. That's correct. on the database based on the tables that have ٥. And the Medicare AWP? been set up. А. I'm sorry, it's Medicaid. ο. What are the tables? Or Medicaid, sorry. When you're populating a database, a ο. Α. AWP. That again is prices that were 8 lot of the things are driven by a table that says 8 A. 9 provided to us by the Department of Justice. 9 what's going to happen with the data. Now, in Exhibit Morgan 003, if you take a I see. I think you have in the past 10 10 ο. look at the fourth full paragraph, the last sentence referred to AWP as, quote, a "benchmark" price. 11 11 12 says, "We also consider the manufacturer's 12 Is that a phrase with which you're familiar? 13 suggested wholesale price in our determination." 13 Α. Yes, sir. Does that refer to your determination What do you mean by that? 15 of Blue Book AWP? 15 When I say benchmark, it's something 16 Α. Yes, sir. 16 that people are used to using from which they How is the manufacturer's suggested ο. make their determinations on how to use the data. 17 17 wholesale price considered in that determination? So it's like, it's a reference that can be used 18 18 19 What role does it play? 19 for whatever use you want to use it for. 20 Α. Well, there are some manufacturers. 20 ο. It is by definition in your terms an 21 and we use the term manufacturers quite loosely, 21 average; is that correct? 22 we're actually talking about any supplier of data 22 Α. That's correct.

37

1/11/2005 Morgan, Patricia Kay

1

10

16

17

18

19

20

21

22

to the database -- and there are things such as repackagers or private label items that do not go through the wholesaler, so you cannot perform a survey on those items, and so those items would be populated in the SWP field but the number would also go into the Blue Book field.

Q. When you say the number would go into the Blue Book field, does it go into some sort of algorithm or computer that calculates an average based on these inputs?

11 MR. KERN: I object to the question 12 as vague and ambiguous. If you're referring 13 to the aforementioned repackagers and 14 relabelers only.

Q. Actually I'm referring to all of the data that you collect. Okay, the various prices from wholesalers or repackagers that you just described. These are different data points coming from different people; is that correct?

MR. SOBOL: Objection to form.

A. That's correct. But we don't average any of that information, or any of that data.

1/11/2005 Morgan, Patricia Kay

1 Q. So you wouldn't expect that it's 2 necessarily the price at which any individual is 3 actually charging or paying for the product?

4 A. I have no knowledge of what anybody 5 pays for product.

6 MR. MORGENSTERN: Would you mark this 7 Exhibit Morgan 004, please.

8 (Exhibit Morgan 004, for 9 identification, Bates-numbered FDB-AWP

10 28850-52, publication sent to customers in

11 1991.)

12 BY MR. MORGENSTERN:

Q. I've shown you what has been marked as Exhibit Morgan 004 for identification, Ms. Morgan.

15 Have you ever seen this before?

A. Yes, sir, I have.

17 Q. What is it?

18 A. It is an article -- or actually it's 19 a publication that went out to your customers in

20 1991.

16

Q. Was this part of a regular -regularly published series of publications by

C/は5世 1:01 Periol 12257-PBS Document 3725-7 Filed 02/08/07005 Page 4号でから

			•
1	Q. Two sentences later it says, quote,	1	when you joined the company, until whatever
2	"It is theoretically possible but highly unlikely	2	changes you referred to before were made in 2003?
3	for AWP to be the price at which a manufacturer,	3	MR. SOBOL: Objection to form.
4	such as Aventis Behring offers a drug to a	4	A. That's correct.
5	wholesaler."	5	Q. And could you describe in general
6	Is that, to your knowledge, a true	6	terms how that was done?
7	statement?	7	MR. SOBOL: Objection.
8	A. That's correct.	8	A. I assume you're asking how we
9	MR. MORGENSTERN: Mark this as	9	determined the markup, is that the question?
10	Exhibit Morgan 007.	10	Q. Yes.
11	(Exhibit Morgan 007, for	11	A. We basically contacted the national
12	identification, document Bates-numbered	12	wholesalers to find out what markup they were
13	FDB-AWP 15102 through 15185, Price Alert,	13	applying to a manufacturer's line, or we could to
14	March 15, 2000.)	14	a specific NDC, if necessary, and then that
15	Q. I would like to show you what has	15	number was entered into a table. And that's
16	been marked as Exhibit Morgan 007 for	16	pretty much it.
17	identification. Can you tell me what that is,	17	Q. So you were asking the wholesalers
18	for the record?	18	for a markup factor that they applied to a
19	A. It appears to be a copy of the	19	company's products?
20	March 15, 2000 Price Alert.	20	A. Correct.
21	Q. This is a more complete version of	21	Q. And
22	what a Price Alert looks like than the previous	22	MR. SOBOL: I'm sorry. I didn't get

45

1/11/2005 Morgan, Patricia Kay

1	exhibit, wh	ich was just the editorial page?
2	A.	It appears so, yes.
3	Q.	And if you turn to page 1 of the
4	Price Alert	, that's the editorial page. Is it
5	not?	
6	A.	Page 3? Oh, I'm sorry.
7	Q.	It's got different page numbers.
8	A.	I'm sorry.
9	Q.	It's FDB0 15104.
10	A.	All right, I'll agree with you now.
11	Q.	Is that the editorial page?
12	A.	That's correct.
13	Q.	And did you write that editorial?
14	A.	Yes, I did.
15	Q.	At the time that you wrote it, was
16	that an acc	urate description of how First Data
17	Bank determ	ined AWP at the time of this
18	publication	?
19	A.	(Reading.) Yes, it is.
20	Q.	Is it the case, Ms. Morgan, that

First Data Bank was using essentially the same

method to determine AWP from the time, at least

21 22

1/11/2005 Morgan, Patricia Kay

	
1	a chance to object, so objection.
2	MR. MORGENSTERN: Okay.
3	Q. And then I think you said sometimes
4	you would survey them with respect to a markup
5	factor on a particular drug as opposed to a whol
6	line?
7	A. To a particular NDC number.
8	Q. An NDC number.
9	A. Right.
10	THE VIDEOGRAPHER: We're going to be
11	going off the record. The time is now
12	10:39 a.m.
13	(Discussion off the record.)
14	THE VIDEOGRAPHER: We're going to be
15	going back on the record. The time is now
16	10:52 a.m.
17	BY MR. MORGENSTERN:
18	Q. Ms. Morgan, I apologize for the
19	disruption. Let's go back to where we were
20	before.
21	You described surveying wholesalers
22	to find the markup factor. Am I correct then

C/456 1:91 Provide 257-PBS Document 3725-7 Filed 02/08/0700 Programment 3725-7

			•
1	that the the information that you're	1	correct?
2	collecting in your survey is not the precise	2	A. That's correct.
3	price of the specific drug, but the markup factor	3	Q. What circumstances would prompt you
4	that the wholesaler is using to mark up either	4	to seek the markup factor for a particular NDC
5	that particular NDC number or when you're	5	number as opposed to for the entire company's
6	surveying for an entire company's products, to	6	products?
7	that company's products?	7	A. Generally an inquiry from a customer
8	MR. KERN: Objection, lacks	8	indicating that what they were hearing back was
9	foundation.	9	different than what we were populating.
10	MR. SOBOL: Objection to form.	10	Q. How often do you survey wholesalers?
11	A. We survey for a markup, and not a	11	A. As the need arises.
12	specific price.	12	MR. SOBOL: Objection to form.
13	Q. Okay. And how would how does the	13	Q. How often were you surveying
14	wholesaler give you the markup factor? What	14	wholesalers in the time period between when you
15	would that do they tell you that it's in the	15	joined the company and 2003?
16	form of a percentage or a multiple of something?	16	A. We survey as the need arises.
17	How is it expressed?	17	Q. And how do you define need?
18	A. Generally as a percentage.	18	A. Changes in the marketplace. Customer
19	Q. And then what do you do with the	19	request to do so.
20	percentage that you get from a particular	20	Q. What kind of changes in the
21	wholesaler?	21	marketplace would prompt you to survey?
22	A. Remember I said generally a	22	A. Mergers, acquisitions, divestitures.

1

8

10

22

49

1/11/2005 Morgan, Patricia Kay percentage. Sometimes they may say that they're

1

13

15

16

17

18

19

source, correct?

2	using these what the manufacturer suggested.
3	Q. Okay.
4	A. So depending upon the response we
5	get, that information is then put into the table
6	that is used to generate the pricing.
7	Q. Okay. And you do this with a number
8	of wholesalers; is that correct?
9	A. We do it with national full-line
10	wholesalers.
11	Q. So the information that's going into
12	the databases is coming from more than one

MR. KERN: Objection, vague and ambiguous.

A. At this point in time, yes, it was.

Q. At this point in time, you mean between the time you joined the company and 2003?

A. That's correct.

Q. Now, you had mentioned that
coccasionally you would survey for the markup
applied to a particular NDC number. Is that

1/11/2005 Morgan, Patricia Kay

I would like to show you what has

been marked as Exhibit Morgan 008 for
identification.
(Exhibit Morgan 008, for
identification, document Bates-stamped
FDB-AWP 2005, from Web site, Frequently
Asked Questions.)
Q. Can you tell me what that is?

- A. It appears to be from our Web site under the frequently asked questions.
- 11 Q. Did you have any role in writing the 12 response to the question, how does First Data 13 Bank determine the BB AWP as published in NDDF 14 Plus and PriceProbe? The top three paragraphs.
- 15 A. (Reading.) It was actually prepared 16 by counsel, and our customer support area, so I 17 don't recall a role in preparing it.
- 18 Q. Okay. Can you tell from this
 19 document when this appeared on your Web site?
 20 A. It's dated 11/4/2002, but I'm not
 21 sure if that's the date it was printed out, or

our date of production.